期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康对HPB-AM细胞MAGE基因表达的影响 被引量：1

Effect of topotecan on MAGE gene expression of HPB-AM cells
原文传递
导出
摘要 目的探讨抗肿瘤新药拓扑替康(TPT)对T细胞淋巴瘤系HPB-AM细胞株黑色素病抗原(MAGE)基因表达的影响。方法以T细胞淋巴瘤系HPB-AM细胞株为研究对象,采用RT-PCR方法检测TPT作用不同时间、不同浓度时对HPB-AM细胞株MAGE基因表达的影响。结果以0.05μmol/L,0.10μmol/L,0.15μmol/L和0.20μmol/L终浓度的TPT作用于HPB-AM细胞,作用12h后检测MAGEmRNA,随着TPT浓度的增加,MAGE-3mRNA和MAGE-4mRNA的表达水平均明显下调,实验组与空白对照组相对表达量比较,在浓度为0.10,0.15和0.20μmol/L的TPT作用后差异具有显著性意义(P<0.05)。用浓度0.10μmol/L的TPT作用于HPB-AM细胞系,作用4,8,12,16h后检测MAGEmRNA,随着TPT作用时间增长,MAGE-3mRNA和MAGE-4mRNA的表达水平明显下调。作用12h和16h后,实验组与空白对照组相对表达量比较差异具有显著性意义(P<0.05)。结论拓扑替康能抑制HPB-AM细胞中MAGEmRNA的表达,且呈剂量和时间依赖性。 Objective To investigate whether topotecan,a novel anti-tumor angent,down-regulates gene expression of melanoma antigen-encoding（MAGE）in HPB-AM cells.Methods MAGE mRNA expression of HPB-AM cells was detected by RT-PCR 4,8,12 and 16 hrs after different concentrations（0.05,0.10,0.15 and 0.20 μmol/L）of topotecan treatment.Results MAGE mRNA expression of HPB-AM cells decreased with increasing concentrations of topotecan 12 hrs after treatment.The MAGE mRNA expression of HPB-AM cells treated by 0.10,0.15 and 0.20 μmol/L of topotecan was significantly lower than that in the blank control group（P〈0.05）.MAGE mRNA expression of HPB-AM cells was significantly reduced in a time-dependent manner after 0.10 μmol/L of topotecan treatment.The MAGE mRNA expression of HPB-AM cells treated by 0.10 μmol/L of topotecan was significantly lower than that in the blank control group 12 and 16 hrs after treatment（P〈0.05）.Conclusions Topotecan is capable of inhibiting the expression of MAGE mRNA of HPB-AM cells in a time-and dose-dependent manner.
作者 雷琦 唐锁勤 王天有
机构地区 解放军总医院小儿内科 首都儿科研究所
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2009年第8期679-682,共4页 Chinese Journal of Contemporary Pediatrics
基金 国家高技术研究发展计划(863)资助(No:2007AA021004)
关键词 MAGE 拓扑替康 HPB-AM细胞 MAGE Topotecan HPB-AM cell
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献10

  • 1van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphoeytes on a human melanoma[J]. Science, 1991, 254(5038) : 1643-1647.
  • 2Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1 [ J ]. Int J Cancer, 1999, 80(2) :219-230.
  • 3De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family[J]. Immunogenetics, 1994, 40(5) :360-369.
  • 4Muscatelli F, Walker AP, De Plaen E, Stafford AN, Monaco AP. Isolation and characterization of a MAGE gene family in the Xp21.3 region[J]. Proc Natl Acad Sci USA, 1995, 92(11): 4987-4991.
  • 5Crump M, Couban S, Meyer R, Rudinskas L, Zanke B, Gluck S, et al. Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study[ J]. Leuk Lymphoma, 2002, 43 ( 8 ) : 1581-1587.
  • 6Russo V, Dalerba P, Ricci A, Bonazzi C, Leone BE, Mangioni C, et al. MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas[J].Int J Cancer, 1996, 67 (3) :457- 460.
  • 7Hara I, Hara S, Miyake H, Yamanaka K, Nagai H, Gohji K, et al. Expression of MAGE genes in testicular germ cell tumors[J]. Urology, 1999, 53(4) :843-847.
  • 8Pratesi G, Tortoreto M, Corti C, Giardini R, Zunino F. Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts[ J]. Br J Cancer, 1995, 71 (3) :525-528.
  • 9De Smet C, Courtois SJ, Faraoni I, Lurquin C, Szikora JP, De Backer O, et al. Involvement of two Ets binding sites in the transcriptional activation of the MAGE1 gene[J]. Immunogenetics, 1995, 42(4) :282-290.
  • 10Mou DC, Cai SL, PengJR, Wang Y, Chen HS, Pang XW,et al. Evaluation of MAGE-1 and MAGE-3 as tumour-specific markers to detect blood dissemination of hepatocellular carcinoma cells [J]. Br J Cancer, 2002, 86(1):110-116.

同被引文献17

  • 1Simon T, Langle A, Harnischmacher U, et al. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high- risk neuroblastoma. Resuhs of a phase- 11 trial[J]. J Cancer Res Clin Oncol, 2007, 133(9): 653-661.
  • 2Santana VM, Furman WL, Billups CA, et al. Improved response inhigh-risk neuroblastoma with protracted topotecan administration using apharmacokinetically guided dosing approach[J]. J Clin Oncol, 2005, 23(18): 4039-4047.
  • 3Brisse HJ, McCarvile MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project[J]. Radiology, 2011,261(1): 243-257.
  • 4Mueller S, Matthay KK. Neuroblastoma: biology and staging[J]. Curr Oncol Rep, 2009, 11(6): 431-438.
  • 5Berthold F, Hero B, Kremens B, et al. Long-term results and risk profiles of patients in five consecutive trials(1979-1997) with stage 4 neuroblastoma over 1 year of age[J]. Cancer Lett, 2003, 197(1- 2): 11-17.
  • 6Broeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment[J]. J Clin Oneol, 1993, 11(8): 1466-1477.
  • 7Kushner BH, Kramer K, Modak S, et al. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma[J]. Cancer, 2010, 116(12): 3054-3060.
  • 8NCI. CTCAE[EB/OL]. [May 17, 2010]. http://evs.nci.nih.gov/ftpl/ CTCAE/About. Html.
  • 9Kaufmann SH, Peereboom D, Buckwaher CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. J Natl Cancer Inst, 1996, 88(11): 734- 741.
  • 10Carol H, Houghton PJ, Morton CL, et al. Initial testing of topotecan by the pediatric preclinical testing program[J]. Pediatr Blood Cancer, 2010, 54(5): 707-715.

引证文献1

二级引证文献1

中国当代儿科杂志
2009年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部